DBV Technologies Cash Flow Conversion Efficiency
DBV Technologies cash flow conversion efficiency. Based on the latest financial reports, DBV Technologies (DBVT) has a cash flow conversion efficiency ratio of -0.518x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-83.08 Million) by net assets ($160.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of DBV Technologies (2011–2025)
Cash flow conversion efficiency of DBV Technologies from 2011 to 2025. This chart illustrates how DBV Technologies's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest DBV Technologies stock price today for real-time trading data and today's change.
DBV Technologies Cash Flow Conversion Ratio Explained
DBV Technologies cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DBV Technologies Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies ranked by their cash flow conversion efficiency. Also see DBVT stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Jingwei Electric Wire Co Ltd
SHE:300120
|
0.053x |
|
China Master Logistics Co Ltd
SHG:603967
|
0.060x |
|
Sichuan Shudao Equipment & Technology Co Ltd
SHE:300540
|
-0.073x |
|
Huarui Electrical Appliance Co Ltd
SHE:300626
|
-0.015x |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
0.027x |
|
Baida Group Co Ltd
SHG:600865
|
0.003x |
|
Ardmore Shipping Corporation
F:A61
|
0.075x |
|
Dongguan Mentech Optical & Magnetic Co Ltd
SHE:002902
|
-0.090x |
Annual Cash Flow Conversion Efficiency for DBV Technologies (2011–2025)
The table below shows the annual cash flow conversion efficiency of DBV Technologies from 2011 to 2025. Review DBV Technologies (DBVT) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $168.77 Million | $-121.18 Million | -0.718x | +81.18% |
| 2024-12-31 | $27.39 Million | $-104.47 Million | -3.815x | -571.38% |
| 2023-12-31 | $140.19 Million | $-79.65 Million | -0.568x | -98.36% |
| 2022-12-31 | $194.45 Million | $-55.70 Million | -0.286x | +73.79% |
| 2021-12-31 | $99.03 Million | $-108.24 Million | -1.093x | -35.63% |
| 2020-12-31 | $205.49 Million | $-165.61 Million | -0.806x | -4.95% |
| 2019-12-31 | $193.19 Million | $-148.35 Million | -0.768x | +31.83% |
| 2018-12-31 | $165.78 Million | $-186.74 Million | -1.126x | -28.02% |
| 2017-12-31 | $182.88 Million | $-160.91 Million | -0.880x | -258.89% |
| 2016-12-31 | $267.90 Million | $-65.68 Million | -0.245x | -195.04% |
| 2015-12-31 | $384.24 Million | $-31.93 Million | -0.083x | +53.34% |
| 2014-12-31 | $182.22 Million | $-32.45 Million | -0.178x | +45.72% |
| 2013-12-31 | $74.09 Million | $-24.31 Million | -0.328x | -23.20% |
| 2012-12-31 | $66.84 Million | $-17.80 Million | -0.266x | +49.14% |
| 2011-12-31 | $19.79 Million | $-10.36 Million | -0.524x | -- |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more